Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yan Liu, Hui Li, Jing Zhu, Yang Zhang, Xianhong Liu, Rixin Li, Qiang Zhang & Ying Cheng. (2021) The Prevalence and Concurrent Pathogenic Mutations of KRAS in Northeast Chinese Non-small-cell Lung Cancer Patients. Cancer Management and Research 13, pages 2447-2454.
Read now
Read now
Hai-bo Shen, Jie Li, Yuan-shan Yao, Zhen-hua Yang, Yin-jie Zhou, Wei Chen & Tian-jun Hu. (2020) Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort. Cancer Management and Research 12, pages 7427-7437.
Read now
Read now
Kamya Sankar, Shirish M Gadgeel & Angel Qin. (2020) Molecular therapeutic targets in non-small cell lung cancer. Expert Review of Anticancer Therapy 20:8, pages 647-661.
Read now
Read now
Daniel Massó-Vallés, Marie-Eve Beaulieu & Laura Soucek. (2020) MYC, MYCL, and MYCN as therapeutic targets in lung cancer. Expert Opinion on Therapeutic Targets 24:2, pages 101-114.
Read now
Read now
Articles from other publishers (44)
Yusuf Acikgoz, Fatma Unal Yildirim, Selin Akturk Esen, Gokhan Ucar, Yakup Ergun, Oznur Bal, Mutlu Dogan & Dogan Uncu. (2023) The Prognostic and Functional Impact of Sprouty 2 Expression in Non–small Cell Lung Cancer. American Journal of Clinical Oncology 46:12, pages 543-550.
Crossref
Crossref
Anneloes L. Noordhof, Esther M. Swart, Ronald A.M. Damhuis, Lizza E.L. Hendriks, Peter W.A. Kunst, Mieke J. Aarts & Wouter H. van Geffen. (2023) Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands. JTO Clinical and Research Reports 4:9, pages 100543.
Crossref
Crossref
Alessandro Di Federico, Ilaria Ricciotti, Valentina Favorito, Sandra Vietti Michelina, Pietro Scaparone, Giulio Metro, Andrea De Giglio, Federica Pecci, Giuseppe Lamberti, Chiara Ambrogio & Biagio Ricciuti. (2023) Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer. Current Oncology Reports 25:9, pages 1017-1029.
Crossref
Crossref
Jhanelle E. Gray, Hil Hsu, Diana Younan, Gaurav Suri, Victoria Chia, Alexander Spira & Melissa Johnson. (2023) Real-world outcomes in patients with KRAS G12C–mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond. Lung Cancer 181, pages 107260.
Crossref
Crossref
Man Wang, Lijie Zhu, Xiaoxu Yang, Jiahui Li, Yu’e Liu & Ying Tang. (2023) Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer. Frontiers in Pharmacology 14.
Crossref
Crossref
Xueyu Duan, Binbin Liao, Xiaobo Liu & Ruixiang Chen. (2023) Efficacy of metformin adjunctive therapy as the treatment for non-diabetic patients with advanced non-small cell lung cancer: A Systematic review and Meta-analysis. Journal of Research in Medical Sciences 28:1, pages 45.
Crossref
Crossref
Shabir Ahmad Ganai, Basit Amin Shah & Manzoor Ahmad Yatoo. 2023. Epigenetic Regulation of Cancer in Response to Chemotherapy. Epigenetic Regulation of Cancer in Response to Chemotherapy
163
198
.
Jiawei Xu, Yiyi Xiong, Zhou Xu, Hongquan Xing, Lingyun Zhou & Xinyi Zhang. (2022) From targeted therapy to a novel way: Immunogenic cell death in lung cancer. Frontiers in Medicine 9.
Crossref
Crossref
Daqi Jia, Leilei Li, Peng Wang, Qiang Feng, Xinyan Pan, Peng Lin, Shuling Song, Lilin Yang & Julun Yang. (2022) ZNF24 regulates the progression of KRAS mutant lung adenocarcinoma by promoting SLC7A5 translation. Frontiers in Oncology 12.
Crossref
Crossref
Jeffrey Mathew Boby, Nurul Nadia Mohd Ghazali, Anita Mani & Mathew George. (2022) Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report. Journal of Medical Case Reports 16:1.
Crossref
Crossref
Yifan Kong, Derek B. Allison, Qiongsi ZhangDaheng HeYuntong LiFengyi MaoChaohao LiZhiguo LiYanquan Zhang, Jianlin WangChi Wang, Christine F. Brainson & Xiaoqi Liu. (2022)
The kinase PLK1 promotes the development of
Kras
/
Tp53
-mutant lung adenocarcinoma through transcriptional activation of the receptor RET
. Science Signaling 15:754.
Crossref
Crossref
Adelina Plangger, Barbara Rath, Sandra Stickler, Maximilian Hochmair, Clemens Lang, Lukas Weigl, Martin Funovics & Gerhard Hamilton. (2022) Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines. Discover Oncology 13:1.
Crossref
Crossref
Serena Ceddia, Lorenza Landi & Federico Cappuzzo. (2022) KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. International Journal of Molecular Sciences 23:16, pages 9391.
Crossref
Crossref
Manuela Spinelli, Persephone Du Parcq, Nandita Gupta, Jamshid Khorashad & Patrizia Viola. (2022) Coexistence of two missense mutations in the KRAS gene in adenocarcinoma of the lung: a possible indicator of poor prognosis. Pathologica 114:3, pages 221-227.
Crossref
Crossref
Jiaqi Liang, Guoshu Bi, Guangyao Shan, Xing Jin, Yunyi Bian & Qun Wang. (2022) Tumor-Associated Regulatory T Cells in Non-Small-Cell Lung Cancer: Current Advances and Future Perspectives. Journal of Immunology Research 2022, pages 1-8.
Crossref
Crossref
Manzar Alam, Shoaib Alam, Anas Shamsi, Mohd Adnan, Abdelbaset Mohamed Elasbali, Waleed Abu Al-Soud, Mousa Alreshidi, Yousef MohammedRabaa Hawsawi, Anitha Tippana, Visweswara Rao Pasupuleti & Md. Imtaiyaz Hassan. (2022) Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer. Frontiers in Oncology 12.
Crossref
Crossref
K. K. Laktionov, A. M. Kazakov, K. A. Sarantseva, D. S. Scherbo & A. P. Koval. (2022) Mutation in the kras gene as a predictor of the effectiveness of immunotherapy for non-small cell lung cancer. Siberian journal of oncology 21:1, pages 115-121.
Crossref
Crossref
Meltem Tan Uygun, Karina Amudi, İrem Doğan Turaçlı & Nurettin Menges. (2021) A new synthetic approach for pyrazolo[1,5-a]pyrazine-4(5H)-one derivatives and their antiproliferative effects on lung adenocarcinoma cell line. Molecular Diversity 26:1, pages 113-124.
Crossref
Crossref
Jawad Barbar, Maria Armach, Mohammad Hassan Hodroj, Sahar Assi, Clara El Nakib, Nathalie Chamseddine & Hazem I Assi. (2022) Emerging genetic biomarkers in lung adenocarcinoma. SAGE Open Medicine 10, pages 205031212211323.
Crossref
Crossref
Mustafa Korkmaz & Melek Karakurt Eryilmaz. (2021) Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature. Anti-Cancer Drugs 33:1, pages e799-e801.
Crossref
Crossref
Fariba Mollarasouli, Nurgul K. Bakirhan & Sibel A. Ozkan. 2022. The Detection of Biomarkers. The Detection of Biomarkers
1
22
.
Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li & Qiming Wang. (2021) MEK inhibitors for the treatment of non-small cell lung cancer. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Adelina Plangger, Barbara Rath, Maximilian Hochmair, Martin Funovics & Gerhard Hamilton. (2021) Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells. Translational Oncology 14:12, pages 101230.
Crossref
Crossref
A.L. Noordhof, R.A.M. Damhuis, L.E.L. Hendriks, A.J. de Langen, W. Timens, B.J.W. Venmans & W.H. van Geffen. (2021) Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. Lung Cancer 155, pages 163-169.
Crossref
Crossref
Giorgia Maroni, Mahmoud A. Bassal, Indira Krishnan, Chee Wai Fhu, Virginia Savova, Rapolas Zilionis, Valerie A. Maymi, Nicole Pandell, Eva Csizmadia, Junyan Zhang, Barbara Storti, Julio Castaño, Riccardo Panella, Jia Li, Corinne E. Gustafson, Sam Fox, Rachel D. Levy, Claire V. Meyerovitz, Peter J. Tramontozzi, Kimberly Vermilya, Assunta De Rienzo, Stefania Crucitta, Daniela S. Bassères, Marla Weetall, Art Branstrom, Alessandra Giorgetti, Raffaele Ciampi, Marzia Del Re, Romano Danesi, Ranieri Bizzarri, Henry Yang, Olivier Kocher, Allon M. Klein, Robert S. Welner, Raphael Bueno, Maria Cristina Magli, John G. Clohessy, Azhar Ali, Daniel G. Tenen & Elena Levantini. (2021) Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. Communications Biology 4:1.
Crossref
Crossref
Shang-Gin Wu, Wei-Yu Liao, Kang-Yi Su, Sung-Liang Yu, Yen-Lin Huang, Chong-Jen Yu, James Chih-Hsin Yang & Jin-Yuan Shih. (2021) Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. JTO Clinical and Research Reports 2:2, pages 100140.
Crossref
Crossref
Kyaw Z. TheinAmadeo B. BiterDavid S. Hong. (2021) Therapeutics Targeting Mutant KRAS. Annual Review of Medicine 72:1, pages 349-364.
Crossref
Crossref
Sunil Kumar, Abhishek Kumar Sharma, H. Lalhlenmawia & Deepak Kumar. 2021. Targeting Cellular Signalling Pathways in Lung Diseases. Targeting Cellular Signalling Pathways in Lung Diseases
821
846
.
Sara W. C. Wen, Rikke F. Andersen, Lena Marie S. Petersen, Henrik Hager, Ole Hilberg, Anders Jakobsen & Torben F. Hansen. (2020) Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma. Cancers 12:12, pages 3728.
Crossref
Crossref
Jing Zheng, Lisha Shen, Nan Jiang, Yanping Zhu, Lihua Wu, He Cao, Wenjia Sun, Jianya Zhou & Jianying Zhou. (2020) First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non–Small-Cell Lung Cancer. Clinical Lung Cancer 21:6, pages 509-519.e1.
Crossref
Crossref
B. Ricciuti, M. Brambilla, A. Cortellini, A. De Giglio, C. Ficorella, A. Sidoni, G. Bellezza, L. Crinò, V. Ludovini, S. Baglivo, G. Metro & R. Chiari. (2019) Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. Clinical and Translational Oncology 22:5, pages 708-716.
Crossref
Crossref
Alice Zamagni, Alice Pasini, Francesca Pirini, Sara Ravaioli, Emanuele� Giordano, Anna Tesei, Daniele Calistri, Paola Ulivi, Francesco� Fabbri, Flavia Foca, Angelo Delmonte & Chiara Molinari. (2020) CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells. International Journal of Oncology.
Crossref
Crossref
Min Yuan, Li-Li Huang, Jian-Hua Chen, Jie Wu & Qing Xu. (2019) The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduction and Targeted Therapy 4:1.
Crossref
Crossref
Wenjun Mao, Yi Wen, Haozhi Lei, Rongguo Lu, Shengfei Wang, Yuheng Wang, Ruo Chen, Yuanyuan Gu, Lin Zhu, Komal K. Abhange, Zachary J. Quinn, Yundi Chen, Fei Xue, Mingfeng Zheng & Yuan Wan. (2019) Isolation and Retrieval of Extracellular Vesicles for Liquid Biopsy of Malignant Ground-Glass Opacity. Analytical Chemistry 91:21, pages 13729-13736.
Crossref
Crossref
Pascale Tomasini, Celine Mascaux, Kevin Jao, Catherine Labbe, Suzanne Kamel-Reid, Tracy Stockley, David M. Hwang, Natasha B. Leighl, Geoffrey Liu, Penelope A. Bradbury, Melania Pintilie, Ming-Sound Tsao & Frances A. Shepherd. (2019) Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer. Clinical Lung Cancer 20:3, pages e338-e345.
Crossref
Crossref
Vienna Ludovini, Biagio Ricciuti, Francesca Tofanetti, Clelia Mencaroni, Diana Giannarelli, Angelo Sidoni, Maria Reda, Annamaria Siggillino, Sara Baglivo, Lucio Crin�, Guido Bellezza, Rita Chiari & Giulio Metro. (2018) KRAS mutation and DNA repair and synthesis genes in non‑small‑cell lung cancer. Molecular and Clinical Oncology.
Crossref
Crossref
Biagio Ricciuti, Sara Baglivo, Vienna Ludovini, Angelo Sidoni, Giulio Metro, Marta Brambilla, Annamaria Siggillino, Maria Sole Reda, Alberto Rebonato, Daniele Maiettini & Rita Chiari. (2018) Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. Lung Cancer 120, pages 70-74.
Crossref
Crossref
Bingkun Zhao, Shanshan Qin, Li Chai, Gaixia Lu, Yuanyou Yang, Huawei Cai, Xueyu Yuan, Suyun Fan, Qingqing Huang & Fei Yu. (2018) Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment. Bioorganic & Medicinal Chemistry 26:5, pages 1086-1091.
Crossref
Crossref
Pan Yang, Wei-Liang Li, Jeff-X Zhou, Yu-Bo Yang & Xia-Xiang Jin. (2017) Peritoneum as the sole distant metastatic site of lung adenosquamous cell carcinoma: a case report. Journal of Medical Case Reports 11:1.
Crossref
Crossref
Pilar Garrido, María Eugenia Olmedo, Ana Gómez, Luis Paz Ares, Fernando López-Ríos, Juan Manuel Rosa-Rosa & José Palacios. (2017)
Treating
KRAS
-mutant NSCLC: latest evidence and clinical consequences
. Therapeutic Advances in Medical Oncology 9:9, pages 589-597.
Crossref
Crossref
Junyu Wu, Zhimin He, Xiao-Mei Yang, Kai-Le Li, Da-Liang Wang & Fang-Lin Sun. (2017) RCCD1 depletion attenuates TGF-β-induced EMT and cell migration by stabilizing cytoskeletal microtubules in NSCLC cells. Cancer Letters 400, pages 18-29.
Crossref
Crossref
Meng Zhu, Liguo Geng, Wei Shen, Yuzhuo Wang, Jia Liu, Yang Cheng, Cheng Wang, Juncheng Dai, Guangfu Jin, Zhibin Hu, Hongxia Ma & Hongbing Shen. (2017) Exome-Wide Association Study Identifies Low-Frequency Coding Variants in 2p23.2 and 7p11.2 Associated with Survival of Non?Small Cell Lung Cancer Patients. Journal of Thoracic Oncology 12:4, pages 644-656.
Crossref
Crossref
Joseph Haddad, Silva Slika & Rami Mahfouz. (2017) Epidermal growth factor receptor (EGFR) in the era of Precision Medicine: The tale of a perfect example of targeted therapy. A review. Meta Gene 11, pages 157-163.
Crossref
Crossref
Yanhong Liu, Feng Wang & Peng Xu. (2017) miR-590 accelerates lung adenocarcinoma migration and invasion through directly suppressing functional target OLFM4. Biomedicine & Pharmacotherapy 86, pages 466-474.
Crossref
Crossref